The discovery of a unique protein could lead to developments in treatments for schizophrenia and other neuropsychiatric disorders, according to scientists.
This news comes following a recent study at the Johns Hopkins University School of Medicine, where scientists from the affiliated Lieber Institute for Brain Development (LIBD) teamed up with experts from AstraZeneca to investigate new approaches to treating diseases of the brain.
The duo discovered a novel, evolved protein – which, according to the May 2016 issue of Nature Medicine, where their full findings were published, could lead to new treatment targets for neuropsychiatric illnesses.
The team’s study identified a human-specific form of an evolved protein derived from AS3MT, which they believe offers a new insight into the ‘causative mechanisms’ of neuropsychiatric disorders.
Experts from AstraZeneca and LIBD have claimed that new approaches to treating the likes of schizophrenia, bipolar disorder, ADHD and depression could all be on the cards for the near future.
A full analysis of the team’s potentially ground-breaking findings can be accessed via the following link: http://www.nature.com/nm/journal/vaop/ncurrent/full/nm.4096.html